Dr. A Velumani, Thyrocare's founder, advises parents against overindulging their children, emphasizing the crucial roles of ...

What struck him most was Redcliffe Labs’ pace. “Had an hour of interaction on how it is going for @Redcliffe Labs. I hear a ...

Franchise-led expansion has been the key driver behind Thyrocare’s strong Q1 performance, with CEO Rahul Guha attributing the 23% revenue growth and 60% profit surge to the addition of 1,500 new ...

Thyrocare founder Dr. A Velumani sparks debate with his viral video criticizing the over-scheduling of city children. He ...

Thyrocare Technologies Limited reported a 62% year-on-year increase in profit after tax (PAT) to ₹38.06 crore for the quarter ended June 30, 2025. The company's revenue from operations grew by 23% to ...

Thyrocare, the healthcare service provider in the diagnostic segment, has unveiled its new brand identity that reflects the dramatic transformation of the company over the last 25 years.

Thyrocare’s consolidated net profit rose 59.9% to INR 38.3 Cr in Q1 FY26 from INR 23.9 Cr in the year-ago quarter ...

While Thyrocare Technologies doesn't seem to have gained much on the EBIT line, at least earnings remain stable for now. There's no doubt that we learn most about debt from the balance sheet.

Thyrocare Technologies has a P/E ratio of 29.82, based on the last twelve months. In other words, at today's prices, investors are paying ₹29.82 for every ₹1 in prior year profit.

Thyrocare Technologies shares zoomed 12.66 per cent in trade, hitting a 52-week high at ₹1,356.95 per share on the BSE.

Thyrocare Technologies' shares soared 13% after reporting a 60% YoY surge in Q1 net profit, bolstered by strong operational revenue growth.

Published :28 Nov 2019, 12:43 AM Updated : 28 Nov 2019, 12:43 AM Thyrocare celebrates 5th anniversary, College of American Pathologists accreditation Thyrocare Bangladesh signs MoU with Telenor Health ...